All posts by imreal

Rampart IC Expands its International Distribution Network


“Rampart’s global mission is to protect as many interventional teams as possible,” said Tom Livingston, Rampart IC CEO. “This year we have expanded our partnerships with several companies, all renowned in their home countries for sourcing and providing the best medical equipment to practitioners.”

Rampart IC, a Birmingham-based medical device company specializing in radiation shielding and orthopedic protection, has signed five distribution agreements that expand their distribution throughout the Middle East, Asia, Europe and North America.

Medpoint Technologies Ltd, headquartered in Israel, will distribute Rampart IC throughout Israel and Palestine. PrismTech, headquartered in Hong Kong, will handle distribution in Hong Kong. Heart Beat Medical Supplies, headquartered in Dubai, will distribute throughout the United Arab Emirates, Qatar, Kuwait, Oman and Egypt. Oryx Medical, headquartered in Toronto, will distribute within Canada.

Rampart IC has existing distribution agreements in place with med tech distributors serving medical facilities throughout Europe, Australia and New Zealand, and Japan. Rampart manages direct sales within the United States.

The Rampart M1128 is a device developed for interventional cardiologists (ICs), but has found its way into several interventional specialties. Interventionalists and their teams spend extended time in catheterization labs and, therefore, rank as the occupation with the highest level of radiation exposure in the world1. ICs often face debilitating injuries resulting from 20-30 pound lead aprons traditionally worn to reduce radiation exposure2, with nearly half reporting some form of orthopedic injury3.

The Rampart IC system is in use with American healthcare systems including Ascension, Sutter Health and Northwell. The technology has been adopted by prestigious medical institutions like Emory University Healthcare System and UAB Medicine.

“Rampart’s global mission is to protect as many interventional teams as possible,” said Tom Livingston, Rampart IC Chief Executive Officer. “This year we have expanded our partnerships with several companies, all renowned in their home countries for sourcing and providing the best medical equipment to practitioners. We are proud to come alongside them and make Rampart IC more widely available, facilitating quality care for patients while protecting the health and safety of interventionalists.”

Statements from the new members of Rampart IC’s distribution network:

“The Rampart system will change X-ray protection in interventional labs and create a new era of protection to the lab team,” said Ruben Cohen, CEO with Medpoint Technologies Ltd. “It is an absolute game changer in the interventional field”

“We at PrismTech are excited to offer our interventional customers in Hong Kong this game changing and value-added solution,” said Raymon Chan, Director, Strategic Business of PrismTech. “We believe this technology will significantly improve the way lab teams are protected from occupational injury.”

“Heart Beat Medical Supplies LLC continues to represent innovation, which provides significant value to healthcare providers,” said Eyad Sadek and Salman Derbieh, Radiology Department Team. “We believe Rampart IC is the future for cath lab safety and is essential in securing the comfort, safety, health and improved quality of life of our healthcare workers.”

“Oryx Medical is excited to bring Rampart to Canada and help better protect Canadian interventionalists,” said Trevor Doran, Managing Director of Oryx. We are passionate to deliver innovation to our healthcare partners and Rampart is delivering game-changing protection around the world. We’re proud to represent a technology that will provide greater protection today and reduce long-term health risks to healthcare professionals simply doing their jobs.”

“Because the safety, comfort and well-being of medical and paramedical teams are at the heart of our concerns, we at SOLYCARE are excited to offer our interventional customers in FRANCE this game changing solution,” said Olivier Mereau, General Manage with SOLYCARE. “We believe Rampart IC will change the way cath lab teams are protected from occupational injury in this strategic healthcare segment.”

Rampart IC is a Birmingham, Alabama-based medical device company specializing in radiation shielding. Praised by the leading interventional cardiologists in the field, Rampart’s technologies have been adopted by prestigious health systems around the globe, including Ascension, Sutter Health and Northwell, and by renowned institutions like Emory University Healthcare System and UAB Medicine.

Visit us at rampartic.com.

1. Zakeri F, Hirobe T, Akbari K. Biological effects of the low–dose radiation exposure on interventional cardiologist. International atomic energy agency: Occ Med ( Lond) 2010;60(6): 464-9

2. Orme NM, Rihal CS, Gulati R, et al. Occupational health hazards of working in the interventional laboratory: a multisite case control study of physicians and allied staff. J Am Coll Cardiol 2015; 65: 820-6.

3. Klein LW, Tra Y, Garratt KN, et al. Society for Cardiovascular Angiography and Interventions. Occupational health hazards of interventional cardiologists in the current decade: Results of the 2014 SCAI membership survey. Catheter Cardiovasc Interv. 2015 Nov; 86(5):913-24.

-30-

Share article on social media or email:

Intellego Technologies, Leader in UV-C Indicator Technology, Debuts New TRI Check Dosimeter Card


UVC Dosimeters make the invisible ‘visible’ by providing real-time, easy to read visuals that give validity to whether the applicable dose on the card has been achieved.

Intellego Technologies Debuts New TRI Check Dosimeter Card

The new TRI Check dosimeters are important indicators for facilities to not only assess if their UV devices are performing, but also confirm that doses of germicidal irradiation have actually been delivered.

Intellego Technologies is pleased to announce the launch of its TRI Check dosimeter, a newly designed ultraviolet dose indicator card created to make measuring and monitoring of UV-C disinfection processes easier than ever. Intellego has tapped Surfacide, the leader in UV-C disinfection, as the first company to utilize the new product in the field with its customers.

Because UV-C is a direct line of sight technology, the importance of being able to audit disinfection devices on a regular basis to ensure UV-C dose and effective device placement and run-times are critical. UVC Dosimeters make the invisible ‘visible’ by providing real-time, easy to read visuals that give validity to whether the applicable dose on the card has been achieved.

The TRI Check dosimeter features an updated layout of its photochromic indicator area and a left-to-right orientation of the color references for 25, 50 and 100 mJ/cm². Based on the popularity of Intellego’s Quick Check dosimeter, the new TRI Check dosimeter also features a check mark icon that becomes visible with UV-C exposure, making it even easier to verify UV-C has been distributed in the space.

Surfacide is the only patented UV-C disinfection system on the market to utilize a trio of ‘robotic’ UV light towers in a single cycle, which has been proven to increase room disinfection coverage over single emitter devices by reducing shadows, time and labor. With an influx of UV companies entering the market during the pandemic, many unfounded claims of efficacy and whole room disinfection have emerged. The new TRI Check dosimeters are important indicators for facilities to not only assess if their UV devices are performing, but also confirm that doses of germicidal irradiation have actually been delivered.

“We’re seeing a new trend emerging in healthcare facilities to take a more committed approach to environmental hygiene monitoring, especially when it comes to enhanced disinfection interventions like UV-C,” said Wendy Walling, Intellego’s Global Director of Marketing. “For years, facilities have been monitoring and auditing their manual cleaning processes per CDC guidelines. Now, some are beginning to apply those same auditing principles to their enhanced disinfection methodologies such as UV-C. Intellego’s UVC Dosimeters make it simple for facilities to evaluate UV-C device performance so they can maximize the benefit of the technology.”

“At Intellego, our mission is to make the benefits of UV-C disinfection visible and help facilities truly see their success with germicidal ultraviolet irradiation. We’re so proud that Surfacide has taken the lead with our UV-C Dosimeters and will be the first to utilize the new TRI Check dosimeter with its customers and sales team,” says Claes Lindahl, CEO, Intellego Technologies.

“Given our Helios System is the only one on the market to use multiple robots in a single cycle, we’re excited to use the new Intellego TRI Check dosimeter cards as they allow us to prove to our customers where the energy from our technology has been delivered, instantly showing them the benefit of using multiple robots versus one during a single cycle,” said Gunner Lyslo, Surfacide Founder and CEO. “These cards are empowering for our industry, especially with the false claims being made by companies in the space, and we are proud to be the first to use them and help lead this effort in transparency.”

About Intellego Technologies:

Intellego Technologies is a research and development company, headquartered in Solna, Sweden. Founded in 2011, Intellego has grown to become the global leader in colorimetric indicators that are utilized worldwide to visually validate the dose of ultraviolet irradiation delivered to surfaces. Through its patented photochromic technology, Intellego manufactures standard and customized indicators that make the benefits of germicidal ultraviolet light visible and promotes the safe, effective and efficient use of UV applications. Intellego’s products support better outcomes with ultraviolet devices in healthcare, food and beverage manufacturing, environmental services, and more. For more information, visit Intellego-Technologies.com and UVCdosimeters.com.

About Surfacide:

Founded in 2010, Surfacide is a UV technology company producing scientifically proven, medical-grade UV devices. Surfacide’s award-winning Helios® System is the world’s only patented, triple emitter ‘robotic’ UV light solution to reduce bacteria, some fungi and viruses. A trusted partner, Surfacide has been deployed in over 500 leading hospitals, nursing homes, dental offices, fire stations, prisons, police stations, commercial office spaces, hotels and public venues worldwide. Surfacide LLC is proud to be American-made and manufactured in Waukesha, WI. Visit the Surfacide website to learn more or contact one of our professional support specialists at (844)-390-3538.

Share article on social media or email:

Middle Tennessee Clinic Offering Ketamine Infusions for Depression, Anxiety, PTSD


Franklin, Tennessee based health and wellness clinic Mindful Infusions of Tennessee has announced an exciting treatment involving Ketamine infusions for anxiety, depression, PTSD and other mood disorders. Mindful Infusions of Tennessee’s innovative Ketamine therapy is capable of providing immediate relief for patients suffering from life altering mood disorders. A recent study published in the Journal of Clinical Psychiatry reports that Ketamine infusion therapy has proven to be successful in reducing mood disorder symptoms in 7 out of 10 patients.

In a recent interview Dr. Rachel Rome, founder and medical director of Mindful Infusion of Tennessee, was asked about her motivation behind opening of the Ketamine clinic. “I realized the astonishing results Ketamine was providing to those suffering with mood and pain disorders and how this incredible treatment was not readily available in our community. As an anesthesiologist and pain interventionist, I felt like my skill set was a perfect fit for this type of practice.”

An additional study conducted by the National Center for Health Statistics revealed that Tennessee ranks number one in adults with symptoms of anxiety or depression. Mindful Infusions of Tennessee’s Ketamine infusion therapy will be a useful tool in combating this mental health crisis by providing potential relief for sufferers of depression, anxiety, and other mood disorders.

About Dr. Rachel Rome: Dr. Rome received her undergraduate degree in biology from Christian Brothers University and her medical degree from the University Tennessee College of Medicine in Memphis, Tennessee. She completed both her residency in anesthesiology and her pain fellowship at the University of Virginia Health Science System in Charlottesville, Virginia. She also has extensive experience in regenerative medicine and palliative care. Dr. Rome is board certified in anesthesiology and in pain management. Currently, she is the medical director of Kindred Palliative Care and Hospice and the former medical director of David Price IMAC Regeneration Center. Dr. Rome is a member of the American Society of Anesthesiologists and The American Society of Interventional Pain Physicians.

Share article on social media or email:

Citeline Announces Winners of the 2022 Scrip Awards, Recognizing Accomplishments in Healthcare


At a live ceremony held Wednesday night in London, Citeline announced the winners of the annual Scrip Awards, recognizing the outstanding accomplishments of those improving human healthcare worldwide. Now in its 18th year, the Scrip Awards spans 16 categories, honoring winners for their work in pharmaceuticals, biotech and allied industries across a wide range of activities.

The 2022 Scrip Award winners by category:


  • MSD’s Innovation Award: Orca Bio’s Orca-T cell therapy
  • China Biopharma Leadership Award – Sponsored by Avance Clinical: BeiGene China
  • Private Financing Deal of the Year: SalioGen Therapeutics’ $130 million Series B financing
  • Clinical Advance of the Year – Sponsored by IQVIA: Daiichi Sankyo and AstraZeneca’s Phase III DESTINY-Breast04 trial of Enhertu in breast cancer
  • Business Development Team of the Year: Synaffix’s Business Development Team
  • Quris Partnership Alliance Award: GRAIL and AstraZeneca for the research, development and commercialization of companion diagnostic assays for early-stage cancer
  • Best Contract Research Organization – Specialist Providers: Veramed
  • Best Contract Research Organization – Full-Service Providers: ICON
  • Licensing Deal of the Year: GSK and Alector for the development and commercialization of AL001 and AL101 for neurodegenerative diseases
  • Community Partnership of the Year – Sponsored by Thermo Fisher Scientific: Regeneron and Society for Science’s Science Talent Search initiative
  • Executive of the Year – Companies with a market cap >$7 billion: Stéphane Bancel, Chief Executive Officer of Moderna
  • Executive of the Year – Private companies and those with a market cap <$7 billion: Michael M. Morrissey, President and Chief Executive Officer of Exelixis
  • WuXi AppTec’s Biotech Company of the Year Award: Moderna
  • Best New Drug – Sponsored by WCG: Immunocore’s Kimmtrak (tebentafusp) for metastatic uveal melanoma
  • Pharma Company of the Year – Sponsored by Parexel: Novo Nordisk
  • Lifetime Achievement Award – Sponsored by ICON: Mads Øvlisen

Details for the award honorees follow:

The celebratory evening began with Orca Bio’s Orca-T cell therapy picking up MSD’s Innovation Award. Using a revolutionary precision cell selection process, Orca-T provides better outcomes for allogeneic hematopoietic stem cell implants in patients at risk of graft-versus-host disease.

The China Biopharma Leadership Award – Sponsored by Avance Clinical was awarded to BeiGene China for bringing innovative and affordable medicines to patients worldwide, including BTK inhibitor Brukinsa, PD-1 antibody tislelizumab in the US, and PARP inhibitor pamiparib in China.

Next up, the accolade for Private Financing Deal of the Year went to SalioGen Therapeutics’ $130 million Series B financing, which far exceeded its original $75 million target, allowing the company to direct the proceeds to its gene coding platform.

Clinical Advance of the Year – Sponsored by IQVIA went to Daiichi Sankyo and AstraZeneca’s Phase III DESTINY-Breast04 trial of Enhertu in breast cancer, the first HER2-directed therapy to show a survival benefit in patients with HER2-low metastatic breast cancer in the DESTINYBreast04 trial.

Synaffix’s highly experienced C-suite executives took honors for Business Development Team of the Year thanks to their successful track record in delivering deals and world-class science in the antibody-drug conjugate (ADC) space. The team signed six licensing deals in the qualifying awards period with deal values around $500 million to $1 billion, with three ADCs already in clinical development.

Next, GRAIL and AstraZeneca accepted the Quris Partnership Alliance Award. The first partnership of its kind, this union combines the expertise of the two companies to research, develop and commercialize companion diagnostic assays for early stage cancer.

Global CRO Veramed earned this year’s prize for Best Contract Research Organization – Specialist Providers for its recent work on COVID-19 with some of the world’s biggest pharmaceutical companies. The company provides quality-driven results for its customers through a collaborative, transparent and people-focused approach.

The Best Contract Research Organization – Full-Service Providers award went to ICON for delivering a unique operational model and varied experience across a wide range of studies, including the first fully decentralized clinical trial approved by the FDA. The company has skilfully leveraged its recent acquisition of PRA Health Sciences for the benefit of its pharma partners.

GSK and Alector combined forces to capture the Scrip Awards’ Licensing Deal of the Year for their agreement to co-develop progranulin-elevating monoclonal antibodies for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s disease.

Another successful joint venture was recognized with Community Partnership of the Year – Sponsored by Thermo Fisher Scientific. Regeneron and Society for Science’s Science Talent Search initiative supports the hard work and novel discoveries of promising leaders inspired to improve the world through STEM.

Turning to recognizing the outstanding contributions of individuals in the industry, the Scrip Awards’ coveted award for Executive of the Year – Companies with a market cap >$7 billion was presented to Stéphane Bancel, Chief Executive Officer of Moderna. Bancel oversaw the development of Moderna’s COVID-19 vaccine and has steered the firm’s incredible growth. Since 2011, he has led Moderna’s transformation from a small Massachusetts-based biotech company into a major worldwide pharma industry player.

The award for Executive of the Year – Private companies and those with a market cap <$7 billion was presented to Michael M. Morrissey, President and Chief Executive Officer of Exelixis. In addition to overseeing expansion of the company’s successful Cometriq/Cabometyx (cabozantinib) franchise to exceed $1 billion in US net revenues in 2021, Morrissey helped usher in a new era of R&D for the company.

Overall excellence in the industry was highlighted with Moderna’s win of the WuXi AppTec’s Biotech Company of the Year Award. Last year, Moderna produced and shipped more than 800 million doses of its COVID-19 vaccine, increased its total revenues from $803 million in 2020 to $18.5 billion in 2021, and built out a global footprint with 11 commercial subsidiaries across North America, Europe and Asia Pacific.

Immunocore’s Kimmtrak (tebentafusp) took the spotlight next as it picked up the prize for Best New Drug – Sponsored by WCG. Kimmtrak is the first approved treatment for patients with unresectable or metastatic uveal melanoma and the first T-cell receptor (TCR) therapeutic to receive regulatory approval. Kimmtrak represents a paradigm shift in treatment for this aggressive form of cancer.

Pharma Company of the Year – Sponsored by Parexel was won by Novo Nordisk, chosen by the Scrip team.

Well known as a diabetes powerhouse, Novo Nordisk broadened its horizons this year, investing millions into cardiovascular and rare diseases R&D. It was busy on the business development front, sealing the $1.1 billion acquisition of Forma Therapeutics and inking innovative deals with Flagship and Ventus.

In the meantime, demand for its weight-loss medicine Wegovy has exceeded expectations and is set to become a game-changing mega-blockbuster at Novo Nordisk which once again has been an industry-leading force in environmental, social and governance (ESG), striving to do business in a financially, environmentally and socially responsible way.

The awards ceremony concluded with the final accolade of the evening, the Lifetime Achievement Award – Sponsored by ICON, which was presented to Mads Øvlisen, chosen by the Scrip team.

Øvlisen dedicated his career in the pharma industry to what is now a 99-year-old global top-20 firm employing around 50,000 people worldwide.

When he joined Novo Industri in 1972 as a young lawyer on a one-year project, it was already a significant insulin supplier, and one with a long and estimable history of research.

He stayed on, becoming CEO in 1981 and overseeing significant product development. Then in 1989 he steered the company through a defining merger with its closest rival, Nordisk Gentofte to create Novo Nordisk. Over the nearly thirty years of his leadership the company’s revenues increased eight-fold, primarily through organic growth.

But Øvlisen valued people before money. One of his key legacies was the emphasis he placed on corporate social responsibility, something he began before it was fashionable. The company was the first in Denmark — and one of the first in the world — to publish an environmental report, in 1994, and it introduced its first corporate social responsibility (CSR) report in 1999.

As CEO, he showed that business success and caring for people went hand in hand. He laid down a set of principles that articulated the founders’ core beliefs in integrity, responsibility, honesty and mutual respect, and made sure that all of the company’s leaders embodied these values.

His commitment to employees, society and the environment saw him appointed to the United Nations Global Compact by Kofi Annan.

Among his many other activities, he has been the chairman of Lego, an adjunct professor in CSR at Copenhagen Business School, co-founder of the European Academy for Society in Business, a member of the Global Impact Board, chairman of the Danish Art Council, chairman of the Royal Danish Ballet and a passionate supporter and sponsor of the arts and artistic research.

“Congratulations to all of this year’s winners and thank you to our headline sponsor ICON and all our other sponsors who have contributed to this fantastic event,” said Alex Shimmings, Executive Editor, Commercial/R&D for Scrip.

“Despite the challenges of the past 18-plus months, the pharma industry has shown both incredible resilience and dedication, which was clearly noticeable in the extremely high quality of entries,” she said.

“We would like to offer a sincere thank you to our judges for their time, extend congratulations to all the nominees for their achievements and, of course, to this year’s winners. We look forward to seeing you all again next year!”

For more information on the Scrip Pharma Awards, visit: pharmaintelligence.informa.com/ScripAwards2022

About Citeline

Citeline powers a full suite of complementary business intelligence offerings to meet the evolving needs of health science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory related decisions and create real-world opportunities for growth.

Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. For more information on one of the world’s most trusted health science partners, visit Citeline.

Autism Learning Partners Launches Center-Based ABA Therapy for Individuals in Flowery Branch, GA


“We’re excited to begin providing center-based ABA care and support in Lawrenceville, Flowery Branch, Gainesville, and surrounding areas,” said Gina T. Chang, Ph.D., BCBA-D, CEO of ALP

ALP strives to give hope, support, and paths of progress for children and their families living with autism and related disorders. With their robust network of community partnerships and ever-growing list of accepted insurances, families can receive quality support. ALP believes a tailored, comprehensive care plan with a dedicated clinical team allows children and their family units to experience the most progress possible.

“We’re excited to begin providing center-based ABA care and support in Lawrenceville, Flowery Branch, Gainesville, and surrounding areas,” said Gina T. Chang, Ph.D., BCBA-D, CEO of ALP. “Our centers offer increased resources, school readiness skills, generalization, a consistent clinical team, social opportunities and caregiver collaboration.”

ALP is a national leader in the special needs field since 1988. Headquartered in Monrovia, CA, they employ over 300 Board Certified Behavior Analysts (“BCBAs”) and have a total workforce of 3,400 nationwide, including Behavior Technicians providing home and center-based Applied Behavior Analysis (ABA) therapies. Services include: ABA care, as well as speech, occupational, physical therapies, and diagnostic services in select regions. ALP now offers treatment in 20 states including California, Colorado, Connecticut, Florida, Georgia, Indiana, Maryland, Massachusetts, Michigan, New Jersey, New Mexico, New York, North Carolina, Ohio, Oregon, Rhode Island, Texas, Utah, Virginia, and Washington.

To learn more about Autism Learning Partners and its services, please visit http://www.AutismLearningPartners.com.

Share article on social media or email:

Meet Magento Florida 2023, the Largest Magento Event in the Southeast Is Set to Take Place February 15th-16th


“Attending #MM23FL presents an opportunity to get face-to-face with like-minded community members who support ongoing growth and continued development of the Magento platform,” said President & CEO of Rave Digital + Aheadworks, Ravi Mittal.

Rave Digital + Aheadworks, 4-time Magento Award-winning Adobe Partners announced they will be coordinating Meet Magento Florida 2023 at the Seminole Hard Rock Hotel & Casino Hollywood – Hollywood, FL February 15th-16th, 2023. With the support of the Magento Association and Adobe Commerce, this will be an in-person event you don’t want to miss!

Meet Magento Florida will attract many Magento community leaders from across the globe, including influencers, merchants, industry leaders, technology partners, experienced developers, retailers, and service providers, as well as acclaimed Magento and Adobe Commerce professionals from across the Globe. All coming together under one roof, to advance the ecosystem of the platform, and the technologies that support it. This is an extraordinary opportunity to be shoulder-to-shoulder with Magento merchants, experienced developers, and technology partners, all of whom will be sharing knowledge and best practices surrounding the Magento platform.

“Attending #MM23FL will have residual benefits! It is an opportunity to get face-to-face with like-minded community members who are exceptional and valuable contributors to the Magento community and who support the ongoing growth and continued development of the platform,” said President * CEO of Rave Digital + Aheadworks, Ravi Mittal.

Buy Your tickets now and save 40% – The early bird rate of $300 will expire on December 31, 2022; tickets will be $500 thereafter. so be sure to take advantage of the discounted rate.

About Rave Digital + Aheadworks

Rave Digital is a top-rated Adobe Commerce Silver Solution Partner. Rave provides end-to-end, eCommerce solutions on Magento Commerce and Open source, for both B2B & B2C clients with a focus on Publishing, Automotive, and Medical industry. Aheadworks is a 4-time award-winning Innovate Exchange Partner with 55+ extensions and 5+ SaaS solutions.

Share article on social media or email:

2023 “Roadmap to Safety” Report to Rate 50 States & DC on Top Traffic Safety Laws to Curb Rising Deaths


New report to unveil best and worst states plus a comprehensive blueprint to boost roadway safety by state governments, Congress and the U.S. Department of Transportation.

2023 “Roadmap to Safety” Report

Over the past 20 years, more than 750,000 people died and 51.5 million more were injured in motor vehicle crashes. Our new Roadmap to Safety is a blueprint for action by each state, Congress and U.S. Transportation Department to curb the rising death toll, said Advocates president Cathy Chase.

The new 2023 “Roadmap to Safety” report will rate 50 states and DC on the passage of 16 optimal traffic safety countermeasures and additional proven solutions to reduce motor vehicle deaths and injuries. The best and worst states will be unveiled plus a comprehensive blueprint to boost roadway safety by state governments, Congress and the U.S. Department of Transportation.

WHAT:

NEWS CONFERENCE – Advocates for Highway and Auto Safety will release the 2023 Roadmap to Safety, the 20th edition of its annual report, detailing 16 optimal traffic safety countermeasures and additional proven solutions to reduce crashes, injuries and deaths. In 2021, traffic deaths spiked to a 16-year high of nearly 43,000, and preliminary 2022 data reveal that fatalities continue to rise.

The 2023 Roadmap report will:


  • Rate each state and DC as green, yellow or red based on their progress toward enacting optimal traffic safety laws.
  • Identify opportunities for state legislatures to close gaps in laws addressing drunk driving, distracted driving, teen driving, seat belt and child safety seat use, motorcycle helmet use, and new this year – automated speed enforcement.
  • Spotlight priorities for safety improvements for federal vehicle standards and roadway infrastructure, including those enacted in 2021 as part of the landmark Infrastructure Investment and Jobs Act.

Safety advocates, crash victims’ loved ones, law enforcement, medical and insurance leaders will present the 2023 report and call for action on state and federal solutions to reverse the upward fatality trend.

WHEN: Tuesday, December 6, 2022 at 10:30am ET

WHERE: This in-person news conference will also be livestreamed at https://saferoads.org. Closed captioning available. Reporters on the livestream can submit questions during the event. Individual interviews with speakers can also be arranged upon request.

News conference location: Top of the Hill Minuteman Ballroom Reserve Officers Association Building 1 Constitution Avenue, NE, Washington, DC 20002

WHO:

  • Cathy Chase, President, Advocates for Highway and Auto Safety (Advocates).
  • Congresswoman Eleanor Holmes Norton (D-DC), Chair, House of Representatives Committee on Transportation and Infrastructure’s Subcommittee on Highways and Transit.
  • Rana Abbas Taylor, Mothers Against Drunk Driving (MADD), of Northville, Michigan. A drunk driver took the lives of Rana’s only sister Rima and her husband Issam, and their children Ali, Isabella, and Giselle. Rana turned her grief into a campaign resulting in passage of 2021 federal legislation requiring technology in all new cars to prevent impaired driving.
  • Matt Gannon, Head of Federal Affairs, Farmers Insurance, Insurance Co-Chair of Advocates’ Board.
  • Chief of Police Jeffrey Glover, Tempe, Arizona.
  • Mary Jagim MS, RN, CEN, FAEN, Past President, Emergency Nurses Association, Consumer Co-Chair of Advocates’ Board.
  • Christine Nizer, Administrator, Maryland Department of Transportation’s Motor Vehicle Administration.

ELECTRONIC MEDIA KIT, including the 2023 Roadmap to Safety report, will be available online Tuesday, December 6, 2022, at 12:01am ET at https://saferoads.org. Embargoed copies of the new report will be made available to the media upon request.

Advocates for Highway and Auto Safety is an alliance of consumer, medical, public health, law enforcement and safety groups and insurance companies and agents working together to make America’s roads safer. Advocates’ mission is the adoption of federal and state laws, policies and programs that prevent motor vehicle crashes, save lives, reduce injuries, and contain costs.

###

Share article on social media or email:

Wilton Manors Vice Mayor Mike Bracchi Appointed to Broward County Medical Marijuana Advisory Board


Florida Probate Law Firm

Florida Probate Law Firm

“I am happy to be able to participate on this Advisory Board and I believe my educational background will allow me to provide valuable input.”

On November 15, 2022, the Broward County Board of County Commissioners appointed Wilton Manors Vice Mayor Mike Bracchi to serve on the Broward County Medical Marijuana Advisory Board. The Advisory Board position is a volunteer position.

Vice Mayor Bracchi stated, “I am honored and humbled to be appointed by the county commission to serve in this important role.” One of the goals of the advisory board is to improve operations and services for growing, processing, and selling medical marijuana for qualified patients and users. Bracchi continued, “I am happy to be able to participate on this Advisory Board and I believe my educational background will allow me to provide valuable input.” Bracchi earned a Doctor of Pharmacy degree and previously practiced as a licensed pharmacist.

Bracchi has been a public servant for many years. He is currently serving as Vice Mayor of Wilton Manors. Bracchi was elected to the Wilton Manors City Commission in 2020, and previously served on the Wilton Manors Budget Review Advisory Committee, where he also served as Chair. Bracchi stated, “I am delighted to continue my public service helping the residents of Broward County by serving in this advisory role.”

About Michael “Mike” Bracchi

Bracchi practices full-time as an attorney and is a Shareholder in the Florida Probate Law Firm, PLLC located in Boca Raton, FL. He is licensed to practice law in Florida and New York and serves as an Arbitrator with the Financial Industry Regulatory Authority. Bracchi has earned several degrees including a Juris Doctor (J.D.), a Doctor of Pharmacy (Pharm.D.), and an M.S. in Business Management and Leadership. He was elected to the Wilton Manors City Commissioner in November 2020.

Contact Info:

Name: Mike Bracchi

Phone: (954) 390-2123

Email: mbracchi@wiltonmanors.com

Share article on social media or email:

Buzz Franchise Brands Partners on New Investment Alongside Leading Private Equity Firm


Buzz Franchise Brands (“Buzz”), a leading multi-brand franchising company, announced today that the company has partnered with leading private equity firm Audax Private Equity (“Audax”) on a passive investment in Medi-Weightloss®, a nationally recognized weight-loss franchise committed to fighting obesity and changing lives.

Headquartered in Tampa, Florida, Medi-Weightloss® operates approximately 100 locations across 27 states. Backed by a team of medical professionals working to create quality weight-loss products and services, Medi-Weightloss® stands out within the healthcare franchise segment, providing physician-supervised, individualized weight-loss plans backed by scientific research and clinical efficacy.

“Buzz has always had a great relationship with Audax, so we’re excited to partner on this investment to drive the growth of Medi-Weightloss®,” said Kevin Wilson, CEO of Buzz Franchise Brands. “Medi operates in the $10 billion market for weight loss, and we see tremendous potential for advancing the brand through the resources and expertise of our team. Medi-Weightloss® aligns with our company mission and values by using evidence-based methods to help people achieve a positive lifestyle change.”

Buzz has a track record of incubating and acquiring service brands within the franchising space. The company transformed outdoor pest-control brand Mosquito Joe from a local business to a powerhouse franchise brand with over 350 locations sold in less than 6 years. Buzz currently operates four brands including Pool Scouts, a pool-cleaning franchise, Home Clean Heroes, a residential house-cleaning franchise, British Swim School, a swim-instruction franchise, and the recently launched holiday-lighting franchise, Grand Illuminations.

“We have always worked hard to provide value to our investors,” added Wilson, who was a Senior Managing Director at Envest Ventures prior to joining Buzz Brands as CEO in 2012. “Investing in Medi-Weightloss® is one more way we can leverage the strength of our team and utilize our franchising experience and expertise in a new way to do that.”

This is the first investment of this type for Buzz, but Wilson indicated Buzz is open to similar opportunities in the future, while continuing to grow the company by adding new brands through incubation or acquisition strategies.

——

About Buzz Franchise Brands

Founded in 2012, Buzz Franchise Brands is a multi-brand franchising company that builds brands that get people talking. The company is the founding franchisor of Mosquito Joe, with a current brand portfolio that includes the Pool Scouts pool cleaning franchise, the Home Clean Heroes residential cleaning franchise, the British Swim School swim instruction franchise, and the recently launched holiday lighting franchise, Grand Illuminations. The company has been recognized by various prominent media outlets as a fast-growing company and top place to work. For more information, visit Buzz Franchise Brands website: buzzfranchisebrands.com or follow us on LinkedIn.

About Audax Private Equity

Audax Group is a leading alternative investment manager with offices in Boston, New York, San Francisco and London. Since its founding in 1999, the firm has raised over $32 billion in capital across its Private Equity and Private Debt businesses. Audax Private Equity has invested over $9 billion in more than 150 platforms and over 1,100 add-on companies, and is currently investing in add-ons out of its $3.5 billion, sixth private equity fund. Through its disciplined Buy & Build approach, Audax seeks to help platform companies execute add-on acquisitions that fuel revenue growth, optimize operations, and significantly increase equity value. With more than 360 employees and over 150 investment professionals, the firm is a leading capital partner for North American middle market companies. For more information, visit the Audax Private Equity website: http://www.audaxprivateequity.com or follow us on LinkedIn.

About Medi-Weightloss®

Established in 2005, Medi-Weightloss® offers a physician-supervised weight loss program known as The One That Works®! Physicians and medical professionals provide individualized care based on each patient’s goals, current health status and medical history. The program includes weekly consultations that focus on nutrition, lifestyle, and exercise. Patients learn how to keep weight off through a specialized Wellness Phase. In addition to weight loss programs for adults – that have resulted in patients losing more than seven million pounds so far – Medi-Weightloss also offers specialized weight loss protocols to address the unique needs of adolescents and people with different health challenges, including metabolic syndrome and diabetes. Visit http://www.mediweightloss.com for more information. Find details about franchise opportunities at http://www.mediweightlossfranchising.com.

Share article on social media or email:

Governor Hochul Vetoes Primary Care Legislation, Misses Opportunity to Advance Health Equity and Primary Care for Underserved New Yorkers


At this point, more than a dozen other states have moved forward with similar policies, and New York has not just failed to lead but has fallen behind.

Primary Care Development Corporation (PCDC) — a New York-based, national nonprofit and Community Development Financial Institution that aims to increase access to primary care and achieve health equity through strategic community investment, capacity building, and policy initiatives — is deeply disappointed that despite months of careful legislative consideration and strong support from health care providers, advocates, and state lawmakers, Governor Hochul vetoed Assembly Bill 7230B/Senate Bill 6534C.

The bill, championed by Health Chairs Senator Gustavo Rivera and Assemblyman Richard Gottfried, was designed to help New York move towards a primary care-centered health care system and ensure that every individual has access to the right care, at the right time, in the right place. Primary care saves lives, leads to improved individual and community health, and is unequivocally central to health equity – yet it is grossly undervalued and underfunded, the effects of which are felt most acutely by low-income communities, communities of color, and rural communities.

This legislation would have started a path to better access to quality primary care for New York’s most vulnerable communities. PCDC CEO Louise Cohen stated, “We are deeply disappointed that Governor Hochul vetoed this legislation and missed a critical opportunity to advance health equity and improve access to primary care for all New Yorkers. At this point, more than a dozen other states have moved forward with similar policies, and New York has not just failed to lead but has fallen behind. We call on Governor Hochul to demonstrate her commitment to a healthier New York by taking concrete steps now and in her next budget to direct the State Departments of Health and Financial Services to increase investment in primary care.”

“I am disappointed by Governor Hochul’s decision to veto my bill, S.6534C, which would have created a primary care reform commission,” said State Senator Gustavo Rivera, sponsor of the bill. “New York State does not invest enough in primary care despite spending more per capita on health care than the national average. I am committed to continuing to work with my colleagues and stakeholders such as PCDC to ensure we address inequitable access to primary care and significantly improve New Yorkers’ health with investments in preventive and non-emergency care.”

PCDC will continue to advocate alongside advocates, health care providers, and lawmakers to increase investment in primary care and improve access to quality primary care for all New Yorkers.

Share article on social media or email: